CHEK1 and medulloblastoma: These results in combination with the lack of differences in CHK1 expression amongst medulloblastoma subgroups suggests that CHK1 upregulation may play a direct role in overall survival of patients with medulloblastoma and thus makes it a critical target for clinical trials.